EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease

Rie Akagawa, Sou Otsuki iD, Minori Sakurazawa, Atsushi Kato, Hironori Furuse, Naomasa Suzuki, Yasuhiro Ikami, Yuki Hasegawa iD, Masaomi Chinushi, Takayuki Inomata

Annals of Noninvasive Electrocardiology · 2026

DOI: 10.1111/anec.70131 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Noninvasive Electrocardiology, 2026. Verfasst von Rie Akagawa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Death, Sudden, Cardiac, Secondary Prevention, Tachycardia, Ventricular. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Implantable cardioverter‐defibrillators (ICD) are first‐line treatment to prevent sudden cardiac death due to recurrent ventricular tachycardia and fibrillation (VT/VF). However, some patients with organic heart disease (OHD) die without ever receiving appropriate ICD therapy. This study aimed to identify predictors of death without appropriate ICD therapy in patients with OHD who received ICD or cardiac resynchronization therapy with a defibrillator (CRT‐D) for secondary prevention.

Methods

We analyzed consecutive patients who received ICD/CRT‐D for secondary prevention between 2000 and 2022. Patients without OHD or those alive without appropriate ICD therapy were excluded. The “no‐benefit group” included patients who died or developed severe disability without appropriate ICD therapy or those who died within 1 year after their first appropriate therapy. The “benefit group” included patients who survived > 1 year after appropriate therapy. Clinical characteristics were compared between the groups.

Results

Of the 170 patients analyzed (median follow‐up: 9.1 years), 43 (25%) were classified into the no‐benefit group (30 died without appropriate therapy, 10 died within 1 year of first appropriate therapy, and 3 developed severe disability without appropriate therapy). Multivariate analyses identified age > 70 years and history of VF as independent predictors of “no benefit.” Among patients with VF aged ≥ 70 years, 71% were classified into the no‐benefit group.

Conclusions

Although 75% of patients benefited from ICD therapy for secondary prevention, elderly patients with VF may gain limited benefits from ICD implantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableDeath, Sudden, CardiacSecondary PreventionTachycardia, VentricularVentricular FibrillationHeart DiseasesHumansMaleFemaleAgedMiddle AgedRetrospective StudiesTreatment OutcomeFollow-Up StudiesElectrocardiographyCardiac Resynchronization Therapy

Stichwörter der Autor:innen

appropriate ICD therapybenefitcardiac resynchronization therapy device with a defibrillator (CRT‐D)elderlyimplantable cardioverter–defibrillator (ICD)secondary preventionventricular fibrillation

Autor:innen und Institutionen

  • Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Niigata University School of Medicine, Niigata, Japan.

ORCID-Profile: Sou Otsuki, Yuki Hasegawa

Zitieren

APA

Akagawa, R., Otsuki, S., Sakurazawa, M., Kato, A., Furuse, H., Suzuki, N., Ikami, Y., Hasegawa, Y., Chinushi, M., & Inomata, T. (2026). Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease. Annals of Noninvasive Electrocardiology. https://doi.org/10.1111/anec.70131

Vancouver

Akagawa R, Otsuki S, Sakurazawa M, Kato A, Furuse H, Suzuki N, et al. Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease. Annals of Noninvasive Electrocardiology. 2026. doi:10.1111/anec.70131

BibTeX
@article{Akagawa2026,
  author = {Akagawa, Rie and Otsuki, Sou and Sakurazawa, Minori and Kato, Atsushi and Furuse, Hironori and Suzuki, Naomasa and Ikami, Yasuhiro and Hasegawa, Yuki and Chinushi, Masaomi and Inomata, Takayuki},
  title = {Benefits of Implantable Cardioverter–Defibrillator for Secondary Prevention in Patients With Organic Heart Disease},
  journal = {Annals of Noninvasive Electrocardiology},
  year = {2026},
  doi = {10.1111/anec.70131}
}
Kostenlos starten →